Spencer Knight’s Post

🎉Exciting news! 🎊 Apeiron to Expand Investment in Synthetic Lethality Pipeline After New Phase in Collaboration with Exscientia! 🎊 July 18, 2024 – San Francisco, USA, and Shanghai, China 🌍Apeiron Therapeutics (Apeiron) announced that it has reached an agreement with Exscientia plc (NASDAQ: EXAI), granting Exscientia full control over GTAEXS617 ('617) and all related intellectual property. This asset is currently in the ELUCIDATE Phase 1/2 clinical trial stage. Under the terms of the agreement, Apeiron will receive an upfront payment of $30 million in cash and equity, in addition to receiving single digit royalties if Exscientia or a third party commercializes '617, which could be worth over $100 million in the upcoming years. The ELUCIDATE trial's monotherapy dose escalation phase aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of '617 in patients with advanced solid tumors. Recruitment for the trial is progressing well. Data from the monotherapy dose escalation phase is expected in the second half of 2024 and transition to a combination dose escalation phase in late 2024 or early 2025. Dr. Mingxi Li, CEO of Apeiron, commented, "Our collaboration with Exscientia has entered a new phase, with Exscientia taking full control of '617 while we remain a supportive shareholder. We are confident in the potential of '617 and believe Exscientia has the resources and capabilities to develop this transformative asset. This transaction enables us to concentrate our efforts on the remainder of our synthetic lethality pipeline and deepen our commitment to providing innovative therapies to cancer patients worldwide. This includes GTA182, a potentially best-in-class next-generation PRMT5 inhibitor, which will soon enter clinical trials.” 🎉 🌎 #expand #investment #successful #biotech #innovation #syntheticlethality #cancerresearch https://lnkd.in/gABsxiHW

The Swiss Biotech Day event has just ended. I wanted to share some thoughts after very interesting conversations and talks. 🖥️ It's simply amazing to see AI revolutionising the pharma and biotech industries, from drug development to clinical trial optimisation. 🧬 Biologics, such as ADCs, nanoparticles (such as exosomes and viral vectors) and cell therapies are sparking conversations for their role, especially in cancer treatments. The potential is thrilling! 🤶 Rejuvenation is marking a new frontier for therapeutic innovation. 💊 The impact of Annex 1 is undeniable, leading to major restructuring for some CDMOs to stay ahead. 💡 Start-up pitches? Pure dynamism and creativity! 💰 Finally, witnessing the strategic investments flowing into Switzerland was a highlight. Multicultural, innovative, government support are the main drivers for investors to look into Swiss companies. #SwissBiotechDay #BiotechInnovation #InvestmentTrends #GlobalBiotech

🗞𝐓𝐡𝐞 𝐛𝐢𝐠𝐠𝐞𝐬𝐭 𝐩𝐫𝐢𝐯𝐚𝐭𝐞 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟒 "The companies BioAge Labs, Latigo Biotherapeutics, Inc., and Neurona Therapeutics bagged the biggest private biotech #investments in February 2024. Around the world, #oncology and #drug discovery players attracted the biggest funding rounds overall. February 2024 saw fewer private biotech funding rounds take place than in January, with 25 rounds in total compared to January’s 38. However, there was still some impressive #fundraising last month, particularly coming out of North America, as the top 10 biggest rounds went to companies based in the U.S." 𝙏𝙤𝙥 𝙥𝙧𝙞𝙫𝙖𝙩𝙚 𝙗𝙞𝙤𝙩𝙚𝙘𝙝 𝙞𝙣𝙫𝙚𝙨𝙩𝙢𝙚𝙣𝙩𝙨 𝙗𝙮 𝙡𝙤𝙘𝙖𝙩𝙞𝙤𝙣: ✅North America: 17 Rounds - 1,222 ($M) ✅Europe: 7 Rounds - 100 ($M) ✅Asia/Pacific: 1 Round - 42 ($M) 👉 Full article: https://lnkd.in/eecmG3-m Source: Labiotech.eu #biotech #investment #medicines #europe #USA #asia #funding

#This_week_in_the_biotech_industry 🔬 Biotech Industry Highlights: Deals, Innovation, and Strategic Moves. This week, the biotech world has been buzzing with transformative developments. Here are the key takeaways: ✅ Major Deals: Novartis spearheaded the week with over $1.8 billion in agreements, including a global license for a groundbreaking muscular dystrophy treatment and a partnership on radiopharmaceuticals for precision oncology. Kyowa Kirin also committed $1.1 billion to collaborate with Kura Oncology on a leukemia drug. 💰 Funding Successes: Enveda, a company using AI to boost nature-based drug discovery, is envisioning clinical success with a $130 million fundraising round. 📉 Operational Adjustments: Cost management remains a focus, as companies like Akari Therapeutics and BioMarin announced layoffs to realign priorities and streamline operations. 📈 Investor Confidence on the Rise: According to Pitchbook, venture capital activity and biotech exits saw an uptick in Q3, signaling renewed optimism in the sector's potential for growth and innovation. The biotech industry continues to strike a balance between trailblazing innovation and strategic efficiency. The future looks promising as breakthroughs unfold. #Biotech #Innovation #Investment #DrugDevelopment #StrategicGrowth

In the words of Panna Sharma, President and CEO of Lantern Pharma (NASDAQ: LTRN): "Our leadership in the innovative use of #AI and #machinelearning to transform costs and timelines in the development of precision oncology therapies has guided three drug development programs in active clinical trials. We believe this pace of development with our focused team and resources should yield significant #future benefits for investors and patients as our industry matures, adopts and accepts a data and AI-centric approach to drug development." https://lnkd.in/gRThYAct #artificialIntelligence #tech #biotech #NVIDIA #AMAZON #GOOGLE

This $208M acquisition is relatively small, but its impact in ADC (especially in ADC safety) may be BIG. I am very interested in Abceutics’ PBSE(Payload-Binding Selectivity Enhancers) technology which may reduce off-target toxicity associated with the ADC's payload.

⏳ The Ynios Pharma campaign ends on Sunday, July 21st ! ⏳ Ynios Pharma is revolutionizing treatments for critical care conditions like Septic Shock and improving kidney transplants. With promising preclinical results, now is the time to invest in this groundbreaking company! 🌟 Why invest? - Huge Market Potential: the intensive care market is valued at $54 billion. The Septic Shock treatment market is set to grow to $21.36 billion by 2030. - Expert Collaborations: partnerships with top specialists like Prof. Jean-Louis Vincent ensure high-quality R&D. - Tax Shelter Advantage: get back 45% of your investment through your 2024 tax return. ❗ Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

Now Accepting Submissions to Support Novel MSC & Exosome Projects with Awards Totaling Up to $100,000 - https://lnkd.in/gsDP559u   RoosterBio Inc.’s Development Award supports innovative early-stage researchers who share its common goals in emerging MSC and exosome-based therapeutics by providing them with the products and process support needed to accelerate their program. It is accepting applications until the end of the week. All applications must be submitted by THIS FRIDAY to be considered!   This award is accepting applications of novel study proposals from researchers located in North America, Europe, Japan, Korea, and Australia. Up to ten award winners will be chosen from diverse focus areas in MSC and exosome research. Each awardee will receive up to $10,000 in select RoosterBio products over a 12-month period. If exosomes or MSCs are your area of research expertise, then I highly encourage you to submit your proposal here: https://lnkd.in/gsDP559u Don't forget, you're down to your final few days to apply! #exosomes #stemcells #msc #research Kim Hastings

Happy Friday, folks. Here is my BioBusiness update for the week with the top ten headlines I found. My BioBusiness updates focus on fund raises, mergers, collaborations, IPOs, and key appointments across biotech, pharma and medical devices. Let me know if I've missed any important pieces of news. ➡ Johnson Matthey sells off medtech metal manufacturing unit to Montagu in $700m private equity deal ➡ Investors fund Prometheus team's 'unfinished business' with $400m for new inflammatory biotech Mirador Therapeutics ➡ Third Rock, Novo Holdings-backed Clasp Therapeutics hooks $150m series A for next-gen cancer treatments ➡ Engrail Therapeutics closes $157M series B, fuelled by investors' renewed interest in neuropsychiatry ➡ Skin care company Galderma's shares soared on Friday after the maker of cosmetic fillers and medical creams made its stock market debut in Switzerland. ➡ Capstan Therapeutics secures $175m oversubscribed Series B with backing from J&J, Bayer and Bristol Myers Squibb ➡ CHARM Therapeutics announces foundation of Scientific Advisory Board, with key experience spanning 3D deep learning and protein structure prediction, drug discovery and oncology. ➡ Basel-headquartered Roche has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich. ➡ British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for $2bn upfront. ➡ Titan Medical to merge with imaging firm Conavi, ending strategic review, focusing on cardiovascular imaging technology. Have a great weekend. #biotech #medicaldevices #pharma